588 EVEREST-1: initial safety data from a seamless phase 1/2 study of A2B530, a logic-gated Tmod CAR T-cell therapy, in patients with solid tumors associated with CEA expression also exhibiting HLA-LOH
Grierson P, Punekar S, Hazim A, Welling T, Simeone D, Kirtane K, Lim K, Morelli M, Patel S, Ulrickson M, Biachi de Castria T, Kundranda M, Vong J, Mitchell J, Langeberg W, Maus M, Bretzlaff W, Nikiforow S, Mardiros A, Maloney D, Liechty K, Locke F, Ng E, Randolph Hecht J, Go W, Molina J. 588 EVEREST-1: initial safety data from a seamless phase 1/2 study of A2B530, a logic-gated Tmod CAR T-cell therapy, in patients with solid tumors associated with CEA expression also exhibiting HLA-LOH. 2024, a670-a671. DOI: 10.1136/jitc-2024-sitc2024.0588.Peer-Reviewed Original Research627 EVEREST-2: a seamless phase 1/2 study of A2B694, a logic-gated Tmod CAR T-cell therapy, in patients with mesothelin-expressing solid tumors with human leukocyte antigen-A*02 loss of heterozygosity
Molina J, Hazim A, Dorigo O, Punekar S, Avila M, Simeone D, Kirtane K, Konecny G, Ward J, Block M, Specht J, Boyd L, Lou Y, Park J, Xuan J, Eskander R, Ong G, Davila M, Langeberg W, Maus M, Mardiros A, Locke F, Wise A, Maloney D, Welch J, Randolph Hecht J. 627 EVEREST-2: a seamless phase 1/2 study of A2B694, a logic-gated Tmod CAR T-cell therapy, in patients with mesothelin-expressing solid tumors with human leukocyte antigen-A*02 loss of heterozygosity. 2024, a721-a722. DOI: 10.1136/jitc-2024-sitc2024.0627.Peer-Reviewed Original ResearchEVEREST-1: A seamless phase 1/2 study of A2B530, a carcinoembryonic antigen (CEA) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors associated with CEA expression also exhibiting human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH).
Molina J, Simeone D, Smith C, Welling T, Kirtane K, Grierson P, Morelli M, Hecht J, Patel S, Locke F, Weng W, Fakih M, Vong J, Liechty K, Ng E, Welch J, Maus M, Maloney D, Go W, Punekar S. EVEREST-1: A seamless phase 1/2 study of A2B530, a carcinoembryonic antigen (CEA) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors associated with CEA expression also exhibiting human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH). Journal Of Clinical Oncology 2024, 42: tps2698-tps2698. DOI: 10.1200/jco.2024.42.16_suppl.tps2698.Peer-Reviewed Original ResearchOff-tumor toxicityT-cell therapyCAR-T cell therapyChimeric antigen receptorHLA-A*02T cellsCarcinoembryonic antigenHLA LOHNormal cellsCEA expressionSolid tumorsRecommended phase 2 doseLack of tumor-specific targetsNon-small cell lungDose-escalation portionPhase 2 doseDose-expansion phaseT-cell engagersObjective of Phase 1Tumor-specific targetingTreating solid tumorsT cell receptorOn-targetBayesian optimal interval designCheckpoint inhibitorsEVEREST-2: A seamless phase 1/2 study of A2B694, a mesothelin (MSLN) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors that show MSLN expression and human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH).
Punekar S, Hecht J, Smith C, Simeone D, Dorigo O, Boyd L, Kirtane K, Ward J, Locke F, Morelli M, Block M, Eskander R, Langeberg W, Liechty K, Ong G, Go W, Maloney D, Maus M, Welch J, Molina J. EVEREST-2: A seamless phase 1/2 study of A2B694, a mesothelin (MSLN) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors that show MSLN expression and human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH). Journal Of Clinical Oncology 2024, 42: tps2699-tps2699. DOI: 10.1200/jco.2024.42.16_suppl.tps2699.Peer-Reviewed Original ResearchChimeric antigen receptorOff-tumor toxicityT-cell therapyCAR-T cell therapyMesothelin expressionT cellsHLA-A*02Solid tumorsNormal cellsChimeric antigen receptor T cellsRecommended phase 2 doseCAR T cell activityLack of tumor-specific targetsNon-small cell lung cancerCryopreserved T cellsMajor body cavitiesPhase 2 doseDose-expansion phaseObjective of Phase 1Tumor-specific targetingCell lung cancerSolid tumor typesFirst-in-humanT cell activationOn-target